Cargando…
Letter comments on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single-centre prospective study: Interaction between lymphopenia and anti-SARS-CoV-2 antibodies after two injections of the Pfizer-BioNTech vaccine in patients with cancers treated by chemotherapy or immunotherapy
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552578/ https://www.ncbi.nlm.nih.gov/pubmed/34810045 http://dx.doi.org/10.1016/j.ejca.2021.09.048 |
| _version_ | 1784591405022183424 |
|---|---|
| author | Sekkate, Sakina Stoeklé, Henri-Corto Mabro, May Billard, David Kennel, Titouan Vasse, Marc Hervé, Christian Beuzeboc, Philippe |
| author_facet | Sekkate, Sakina Stoeklé, Henri-Corto Mabro, May Billard, David Kennel, Titouan Vasse, Marc Hervé, Christian Beuzeboc, Philippe |
| author_sort | Sekkate, Sakina |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8552578 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85525782021-10-29 Letter comments on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single-centre prospective study: Interaction between lymphopenia and anti-SARS-CoV-2 antibodies after two injections of the Pfizer-BioNTech vaccine in patients with cancers treated by chemotherapy or immunotherapy Sekkate, Sakina Stoeklé, Henri-Corto Mabro, May Billard, David Kennel, Titouan Vasse, Marc Hervé, Christian Beuzeboc, Philippe Eur J Cancer Letter to the Editor Elsevier Ltd. 2022-01 2021-10-28 /pmc/articles/PMC8552578/ /pubmed/34810045 http://dx.doi.org/10.1016/j.ejca.2021.09.048 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Sekkate, Sakina Stoeklé, Henri-Corto Mabro, May Billard, David Kennel, Titouan Vasse, Marc Hervé, Christian Beuzeboc, Philippe Letter comments on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single-centre prospective study: Interaction between lymphopenia and anti-SARS-CoV-2 antibodies after two injections of the Pfizer-BioNTech vaccine in patients with cancers treated by chemotherapy or immunotherapy |
| title | Letter comments on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single-centre prospective study: Interaction between lymphopenia and anti-SARS-CoV-2 antibodies after two injections of the Pfizer-BioNTech vaccine in patients with cancers treated by chemotherapy or immunotherapy |
| title_full | Letter comments on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single-centre prospective study: Interaction between lymphopenia and anti-SARS-CoV-2 antibodies after two injections of the Pfizer-BioNTech vaccine in patients with cancers treated by chemotherapy or immunotherapy |
| title_fullStr | Letter comments on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single-centre prospective study: Interaction between lymphopenia and anti-SARS-CoV-2 antibodies after two injections of the Pfizer-BioNTech vaccine in patients with cancers treated by chemotherapy or immunotherapy |
| title_full_unstemmed | Letter comments on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single-centre prospective study: Interaction between lymphopenia and anti-SARS-CoV-2 antibodies after two injections of the Pfizer-BioNTech vaccine in patients with cancers treated by chemotherapy or immunotherapy |
| title_short | Letter comments on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single-centre prospective study: Interaction between lymphopenia and anti-SARS-CoV-2 antibodies after two injections of the Pfizer-BioNTech vaccine in patients with cancers treated by chemotherapy or immunotherapy |
| title_sort | letter comments on: efficacy and safety of bnt162b2 vaccination in solid cancer patients receiving anti-cancer therapy - a single-centre prospective study: interaction between lymphopenia and anti-sars-cov-2 antibodies after two injections of the pfizer-biontech vaccine in patients with cancers treated by chemotherapy or immunotherapy |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552578/ https://www.ncbi.nlm.nih.gov/pubmed/34810045 http://dx.doi.org/10.1016/j.ejca.2021.09.048 |
| work_keys_str_mv | AT sekkatesakina lettercommentsonefficacyandsafetyofbnt162b2vaccinationinsolidcancerpatientsreceivinganticancertherapyasinglecentreprospectivestudyinteractionbetweenlymphopeniaandantisarscov2antibodiesaftertwoinjectionsofthepfizerbiontechvaccineinpatientswithcancerstreate AT stoeklehenricorto lettercommentsonefficacyandsafetyofbnt162b2vaccinationinsolidcancerpatientsreceivinganticancertherapyasinglecentreprospectivestudyinteractionbetweenlymphopeniaandantisarscov2antibodiesaftertwoinjectionsofthepfizerbiontechvaccineinpatientswithcancerstreate AT mabromay lettercommentsonefficacyandsafetyofbnt162b2vaccinationinsolidcancerpatientsreceivinganticancertherapyasinglecentreprospectivestudyinteractionbetweenlymphopeniaandantisarscov2antibodiesaftertwoinjectionsofthepfizerbiontechvaccineinpatientswithcancerstreate AT billarddavid lettercommentsonefficacyandsafetyofbnt162b2vaccinationinsolidcancerpatientsreceivinganticancertherapyasinglecentreprospectivestudyinteractionbetweenlymphopeniaandantisarscov2antibodiesaftertwoinjectionsofthepfizerbiontechvaccineinpatientswithcancerstreate AT kenneltitouan lettercommentsonefficacyandsafetyofbnt162b2vaccinationinsolidcancerpatientsreceivinganticancertherapyasinglecentreprospectivestudyinteractionbetweenlymphopeniaandantisarscov2antibodiesaftertwoinjectionsofthepfizerbiontechvaccineinpatientswithcancerstreate AT vassemarc lettercommentsonefficacyandsafetyofbnt162b2vaccinationinsolidcancerpatientsreceivinganticancertherapyasinglecentreprospectivestudyinteractionbetweenlymphopeniaandantisarscov2antibodiesaftertwoinjectionsofthepfizerbiontechvaccineinpatientswithcancerstreate AT hervechristian lettercommentsonefficacyandsafetyofbnt162b2vaccinationinsolidcancerpatientsreceivinganticancertherapyasinglecentreprospectivestudyinteractionbetweenlymphopeniaandantisarscov2antibodiesaftertwoinjectionsofthepfizerbiontechvaccineinpatientswithcancerstreate AT beuzebocphilippe lettercommentsonefficacyandsafetyofbnt162b2vaccinationinsolidcancerpatientsreceivinganticancertherapyasinglecentreprospectivestudyinteractionbetweenlymphopeniaandantisarscov2antibodiesaftertwoinjectionsofthepfizerbiontechvaccineinpatientswithcancerstreate |